Shenzhen Neptunus Bioengineering Co Ltd (SHE:000078) — Market Cap & Net Worth
Market Cap & Net Worth: Shenzhen Neptunus Bioengineering Co Ltd (000078)
Shenzhen Neptunus Bioengineering Co Ltd (SHE:000078) has a market capitalization of $565.97 Million (CN¥3.87 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #11747 globally and #3389 in its home market, demonstrating a -3.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shenzhen Neptunus Bioengineering Co Ltd's stock price CN¥1.47 by its total outstanding shares 2631123257 (2.63 Billion). Review debt load of Shenzhen Neptunus Bioengineering Co Ltd to assess the company's total debt and financial obligations.
Shenzhen Neptunus Bioengineering Co Ltd Market Cap History: 2015 to 2026
Shenzhen Neptunus Bioengineering Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $3.62 Billion to $565.97 Million (-12.67% CAGR).
Shenzhen Neptunus Bioengineering Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shenzhen Neptunus Bioengineering Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Shenzhen Neptunus Bioengineering Co Ltd's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.38 Billion | $13.61 Billion | $418.40 Million | 0.18x | 5.69x |
| 2017 | $2.23 Billion | $24.94 Billion | $636.38 Million | 0.09x | 3.51x |
| 2018 | $1.14 Billion | $38.38 Billion | $414.69 Million | 0.03x | 2.75x |
| 2019 | $1.44 Billion | $41.49 Billion | $206.40 Million | 0.03x | 6.96x |
| 2020 | $1.54 Billion | $40.02 Billion | -$288.53 Million | 0.04x | N/A |
| 2021 | $1.36 Billion | $41.05 Billion | $93.30 Million | 0.03x | 14.57x |
| 2022 | $1.28 Billion | $37.83 Billion | -$1.03 Billion | 0.03x | N/A |
| 2023 | $1.21 Billion | $36.42 Billion | -$1.69 Billion | 0.03x | N/A |
| 2024 | $981.79 Million | $30.32 Billion | -$1.19 Billion | 0.03x | N/A |
| 2025 | $1.33 Billion | $26.67 Billion | -$563.06 Million | 0.05x | N/A |
Competitor Companies of 000078 by Market Capitalization
Companies near Shenzhen Neptunus Bioengineering Co Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Shenzhen Neptunus Bioengineering Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Shenzhen Neptunus Bioengineering Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Shenzhen Neptunus Bioengineering Co Ltd's market cap moved from $3.62 Billion to $ 565.97 Million, with a yearly change of -12.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥565.97 Million | -57.51% |
| 2025 | CN¥1.33 Billion | +35.69% |
| 2024 | CN¥981.79 Million | -18.79% |
| 2023 | CN¥1.21 Billion | -5.42% |
| 2022 | CN¥1.28 Billion | -5.95% |
| 2021 | CN¥1.36 Billion | -11.97% |
| 2020 | CN¥1.54 Billion | +7.51% |
| 2019 | CN¥1.44 Billion | +25.89% |
| 2018 | CN¥1.14 Billion | -48.87% |
| 2017 | CN¥2.23 Billion | -6.35% |
| 2016 | CN¥2.38 Billion | -34.27% |
| 2015 | CN¥3.62 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Shenzhen Neptunus Bioengineering Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $565.97 Million USD |
| MoneyControl | $565.97 Million USD |
| MarketWatch | $565.97 Million USD |
| marketcap.company | $565.97 Million USD |
| Reuters | $565.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shenzhen Neptunus Bioengineering Co Ltd
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and othe… Read more